Naltrexone Ophthalmic - Ocunova Inc.

Drug Profile

Naltrexone Ophthalmic - Ocunova Inc.

Alternative Names: OCU 001

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocunova
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Eye disorder therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 26 Mar 2018 Chemical structure information added
  • 09 Feb 2018 Phase-I clinical trials in Dry eyes (Ophthalmic) (Before February 2018)
  • 09 Feb 2018 Preclinical trials in Dry eyes in USA (Ophthalmic) (Before February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top